ResearcherTongde Hospital of Zhejiang ProvinceNo recent work listed

Fengyong Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2970-2407; OpenAlex author ID A5010179562. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 1

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper

Papers 2

Retraction Note to: Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the Co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer… Co-author DOI 10.1007/s11095-022-03181-6 ↗
Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment. Co-author DOI 10.1007/s11095-020-02949-y ↗

Closest collaborators

The 1 strongest of 1 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Zhen Zhang · 2 shared papers, 2020–2022 · strength 0.57
- Paper Retraction Note to: Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the Co-Delivery of KRAS-siR… DOI 10.1007/s11095-022-03181-6 ↗
- Paper Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine f… DOI 10.1007/s11095-020-02949-y ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.